Skip to content
    VCYT
    Earnings call· Dec 2025(Q4 FY25)

    VERACYTE Q4 FY25 earnings call VCYT

    Feb 25, 2026 Source

    Executive summary

    Veracyte Q4 FY25 — Strong Core Growth and Early Profitability Target Achievement

    Veracyte delivered a strong Q4 FY25, driven by robust performance in its core Decipher and Afirma testing businesses, which continue to show double-digit growth and market penetration. The company significantly exceeded its adjusted EBITDA margin target a year early, providing flexibility for strategic investments. Looking ahead, Veracyte is poised for multiple product launches in 2026, including TrueMRD for bladder cancer and Prosigna for breast cancer, which are expected to be key revenue drivers in 2027 and beyond.

    Highlights

    5
    • Total revenue reached $141 million in Q4 FY25, representing 19% year-over-year growth.

    • Full-year 2025 total revenue was $517 million, at the high end of guidance and representing 16% growth.

    • Adjusted EBITDA margin exceeded 27% for FY25, surpassing the 25% target more than a year ahead of plan.

    • Decipher achieved its 15th consecutive quarter of more than 20% year-over-year volume growth, with Q4 volume up 21%.

    • Cash and cash equivalents increased by over $120 million during FY25, reaching $412.9 million by year-end.

    Concerns

    2
    • The company anticipates a $10 million headwind in 2026 from prior period collections recognized in 2025.

    • Q1 FY26 adjusted EBITDA margin is expected to be lower than the full-year guidance and sequentially down from Q4 FY25 due to typical seasonality of expenses.

    Guidance & targets

    9
    CategoryTargetConfidence
    Total Revenue
    $570M-$582M
    high materiality
    High
    Testing Revenue Growth
    14%-16%
    high materiality
    High
    Afirma Revenue Growth
    mid- to high single digits
    medium materiality
    High
    Decipher Revenue Growth
    approximately 20%
    medium materiality
    High
    Adjusted EBITDA Margin
    approximately 25%
    high materiality
    High
    Q1 Adjusted EBITDA Margin
    lower
    medium materiality
    High
    New Product Launch Revenue Contribution
    not included in 2026 revenue guidance
    medium materiality
    High
    Biopharma Revenue
    less than $1M
    low materiality
    High
    Product Revenue (IVD)
    around $10M
    medium materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Total Company
    Q4 FY25 total revenue and volume growth, reflecting strong performance across core businesses. Full-year 2025 total revenue was $517M, representing 16% growth.
    Total testing volume: 48,000 testsTotal testing volume growth: 16% YoYPatients served to date: over 800,000Patients tested in 2025: over 100,000
    $141M19%
    Core Testing Business
    Driven by strong volume and average selling price (ASP).
    21%
    Decipher
    Achieved record numbers for quarterly ordering providers and orders per physician. Strong growth in high-risk RP and metastatic categories (over 30% growth).
    Tests delivered: 27,200 (Q4)Market penetration: approximately 33%Ordering physicians increased: 18% YoY (Q4)Consecutive quarters of >20% YoY volume growth: 15
    27% (revenue), 21% (volume)
    Afirma
    Continued pipeline of new account wins and increased utilization per account. Completed full transition to v2 transcriptome, improving scalability and cost-effectiveness.
    Tests delivered: 18,250 (Q4)Market share: approximately 38%No result rate: 2% (Q4, lower than prior quarter)
    16% (revenue), 12% (volume)

    Operational metrics

    20
    Non-GAAP Gross Margin
    75.1%up 580 bps
    Q4 FY25

    Compared to prior year period.

    Testing Gross Margin
    76.1%up 380 bps
    Q4 FY25

    Compared to prior year, driven by operational efficiencies from v2 transcriptome and higher prior period collections (PPCs).

    Non-GAAP Operating Expenses
    $65.1Mup 12%
    Q4 FY25

    Year-over-year increase.

    R&D Expenses
    $19Mup $1.6M
    Q4 FY25

    Driven primarily by clinical investments.

    Sales and Marketing Expenses
    $23.9Mslightly up
    Q4 FY25

    Given higher travel expense.

    G&A Expenses
    $22.3Mup $4.7M
    Q4 FY25

    Primarily due to hiring and expenses in customer service and software teams.

    Adjusted EBITDA
    $42.3M
    Q4 FY25

    Well above expectations given benefit of prior period collections.

    Adjusted EBITDA Margin
    27.6%
    FY25

    Ahead of target of 25%, achieved more than a year ahead of projections.

    Cash and Cash Equivalents
    $412.9Mincreased by more than $120M (FY25)
    Q4 FY25 end

    Balance on hand at the end of the quarter.

    Testing ASP
    $2,984up 4%
    Q4 FY25

    Compared to prior year, driven primarily by the impact of higher prior period collections (PPCs).

    Normalized Testing ASP
    $2,875up 1%
    Q4 FY25

    Compared to prior year, after adjusting for the approximate impact of $5 million of PPCs in the quarter.

    Decipher High-Risk RP and Metastatic Growth
    more than 30%
    Q4 FY25

    Growth in combined high-risk RP and metastatic categories, driven by Decipher metastatic launch.

    Decipher Slides Scanned
    over 210,000
    to date

    From over 150,000 patients with outcomes data, representing the majority of historical Decipher data set.

    Decipher Publications
    more than 100
    to date

    Demonstrating clinical utility and validity across the prostate cancer risk spectrum.

    Decipher GRID Publications
    additional 100
    to date

    Leveraging the research use-only GRID platform.

    Afirma No Result Rate
    2%lower than prior quarter
    Q4 FY25

    Directly contributing to more patients and physicians receiving actionable results, enabled by v2 transcriptome.

    TrueMRD MIBC Market Size (SAM)
    around 20,000
    annual

    Estimated serviceable addressable market for MIBC.

    GAAP Net Income
    $41.1M
    Q4 FY25

    Quarterly GAAP net income.

    GAAP Net Income
    $66.4M
    FY25

    Full-year 2025 GAAP net income.

    Effective Tax Rate
    mid-single digits
    FY26

    Expected GAAP and non-GAAP tax rate for FY26, still with a decent chunk of NOLs.

    Industry KPIs

    5
    MetricValueDetails
    Pipeline read out calendarMultiple
    Regulatory approvals filingsTrueMRD MIBC
    Therapeutic drug market shareAfirma: approximately 38%, Decipher: approximately 33%%
    Clinical trial efficacy safety dataPositive outcomes data
    Cumulative patients uptake since launchover 800,000patients

    Product announcements

    4
    ProductTypeDetails
    Decipher for metastatic patientslaunch
    TrueMRDlaunch
    Prosignalaunch
    Afirma GRIDupdate

    Risks & headwinds

    6
    Prior Period Collections (PPCs) HeadwindFY26

    $10 million

    Mitigation: Factored into 2026 guidance, but not explicitly included in revenue projections.

    Seasonality of ExpensesQ1 FY26

    Q1 adjusted EBITDA margin expected to be lower

    Mitigation: Expenses are planned on an annual rather than quarterly basis; typical seasonality includes increased compensation, benefits, and payroll tax.

    Weather Impact on Decipher VolumeQ1 FY26

    tracking to date is around the same from a weather impact

    Mitigation: Expect to catch up throughout the course of the year.

    New Product Launch Revenue ContributionFY26

    not included in 2026 revenue guidance

    Mitigation: New product launches (TrueMRD, Prosigna) are expected to be more significant revenue drivers in 2027 and beyond; 2026 focus is on customer experience and KOL engagement.

    Biopharma Revenue ContributionFY26

    less than $1 million

    Mitigation: Company's philosophy is to only include signed and booked biopharma revenue; focus is on evidence strategy rather than revenue generation.

    Product Revenue (IVD) DeclineFY26

    around $10 million (down year-over-year)

    Mitigation: Due to a new contract manufacturer and the decision not to sell the IVD to U.S. customers ahead of the LDT launch.

    What to watch in Q1 FY26

    5

    Afirma No Result Rate

    Next quarter
    Current2%
    TargetContinued low rate, contributing to volume

    Why it matters

    A low no-result rate directly contributes to more actionable results for patients and physicians, supporting Afirma's volume growth and market penetration.

    In the fourth quarter, our [ no ] result rate was 2% lower than in the prior quarter, directly contributing to more patients and physicians receiving actionable results to support clinical decision-making.

    Q&A highlights

    7

    Has conviction in 2026 guidance evolved, what drives high/low end, and what is the quarterly cadence?

    Management reiterated strong conviction in 2026 guidance. Q1 is expected to be seasonally lower due to prior period collections (PPCs) not repeating and typical start-of-year expenses. High-end drivers include Afirma no-result rate benefit, potential PPCs, and Decipher volume outperformance. New product launches are not included in 2026 revenue guidance, as they are expected to be 2027 drivers.

    No, just a reminder that we're not -- in our guide for revenue, we're not guiding for the new product launches for a very simple reason that we expect those to be more of a revenue driver in 2027, but those, of course, aren't included in the guidance either.

    asked by Subhalaxmi Nambi · answered by Marc Stapley

    3 min read6 chapters

    Detailed Narrative

    01

    Core Business Momentum and Market Penetration

    Veracyte's core testing business, driven by Decipher and Afirma, demonstrated robust performance in Q4 FY25. Decipher achieved its 15th consecutive quarter of over 20% year-over-year volume growth, reaching approximately 33% market penetration. Afirma also showed strong growth, with 12% volume increase and an estimated 38% market share. The full transition of Afirma to the v2 transcriptome platform has improved operational efficiency and reduced the 'no result' rate to 2%, directly contributing to more actionable patient results.

    02

    TrueMRD Launch and Pipeline Expansion

    The company is on track to launch its first TrueMRD indication for muscle invasive bladder cancer (MIBC) in the first half of 2026, following technology assessment with MolDX. This whole-genome sequencing approach is differentiated and aims to serve approximately 70% of MIBC cases in the urology and radiation oncology setting, focusing initially on recurrence monitoring. TrueMRD is supported by a growing body of clinical evidence, with studies like the Phase II trial evaluating pembro with serial ctDNA monitoring highlighting its potential for bladder-sparing strategies. The platform is extensible, with a deep pipeline of additional studies across various cancer types.

    03

    Prosigna for Breast Cancer and OPTIMA Trial

    Prosigna, based on the PAM50 signature, is slated for a U.S. LDT launch in summer 2026 for early-stage breast cancer patients. This market represents a significant opportunity, with approximately 225,000 eligible patients annually. The full readout of the OPTIMA trial, expected at ASCO in June 2026, is anticipated to further strengthen Prosigna's clinical evidence and differentiate it as a standard in breast cancer prognosis. Veracyte is building its commercial and medical liaison teams in preparation for the launch.

    04

    Exceeding Profitability Targets and Capital Allocation

    Veracyte achieved an adjusted EBITDA margin of 27.6% for FY25, surpassing its 25% target more than a year ahead of schedule. This strong profitability, coupled with a cash balance increase of over $120 million to $412.9 million, provides significant financial flexibility. The company plans to strategically invest in growth drivers, including new product launches, clinical evidence development, and infrastructure, while maintaining a profitable profile. Capital allocation remains focused on organic growth, discovery, and potential market opportunities.

    05

    Clinical Evidence and Platform Strategy

    Generating clinical evidence is a core pillar of Veracyte's strategy. The Decipher platform boasts over 100 publications demonstrating clinical utility and an additional 100 leveraging its GRID platform. New predictive signatures like PORTOS, PTEN, and PAM50 are being integrated into Decipher reports to provide additional insights for high-risk and metastatic prostate cancer patients. The company is also leveraging digital pathology and AI-powered analysis to enhance tumor assessment and expand collaborations with academic centers, reinforcing its commitment to evolving clinical offerings.

    06

    Competitive Landscape and Growth Drivers

    Despite a competitive market, Decipher continues to demonstrate strong growth, driven by extensive clinical evidence and NCCN guideline recognition. Management reports no significant change in competitive dynamics, with Veracyte's growth largely independent of competitor performance. The company sees significant opportunity for further penetration in the two-thirds of prostate cancer patients not yet tested, particularly in the high-risk and metastatic categories, which are growing at over 30%.

    AI-generated summary of the company’s earnings call. Not investment advice.